E
Edward G. Shaw
Researcher at Wake Forest University
Publications - 228
Citations - 14119
Edward G. Shaw is an academic researcher from Wake Forest University. The author has contributed to research in topics: Radiation therapy & Radiosurgery. The author has an hindex of 53, co-authored 220 publications receiving 12670 citations. Previous affiliations of Edward G. Shaw include University of Rochester & University of Edinburgh.
Papers
More filters
Journal ArticleDOI
Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05.
Edward G. Shaw,Charles Scott,Luis Souhami,Robert P. Dinapoli,Robert W. Kline,Jay S. Loeffler,Nancy C. Farnan +6 more
TL;DR: The maximum tolerated doses of single fraction radiosurgery in patients with recurrent previously irradiated primary brain tumors and brain metastases were defined for this population of patients as 24 Gy, 18 Gy, and 15 Gy for tumors, whereas investigators' reluctance to escalate to 27 Gy, rather than excessive toxicity, determined the maximum tolerated dose.
Journal ArticleDOI
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Gregory Cairncross,Meihua Wang,Edward G. Shaw,Robert B. Jenkins,David Brachman,Jan C. Buckner,Karen Fink,Luis Souhami,Normand Laperriere,Walter J. Curran,Minesh P. Mehta +10 more
TL;DR: For the subset of patients with 1p/19q codeleted AO/AOA, PCV plus RT may be an especially effective treatment, although this observation was derived from an unplanned analysis.
Journal ArticleDOI
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Jan C. Buckner,Edward G. Shaw,Stephanie L. Pugh,Arnab Chakravarti,Mark R. Gilbert,Geoffrey R. Barger,Stephen W. Coons,Peter Ricci,Dennis E. Bullard,Paul D. Brown,Keith J. Stelzer,David Brachman,John H. Suh,Christopher J. Schultz,Jean Paul Bahary,Barbara Fisher,Barbara Fisher,Harold Kim,Albert Murtha,Erica Hlavin Bell,Minhee Won,Minesh P. Mehta,Walter J. Curran +22 more
TL;DR: In a cohort of patients with grade 2 glioma who were younger than 40 years of age and had undergone subtotal tumor resection or who were 40 yearsof age or older, progression-free survival and overall survival were longer among those who received combination chemotherapy in addition to radiation therapy than amongThose who received radiation therapy alone.
Journal ArticleDOI
A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma
Robert B. Jenkins,Hilary E. Blair,Karla V. Ballman,Caterina Giannini,Robert M. Arusell,Mark E. Law,Heather C. Flynn,Sandra M. Passe,Sara J. Felten,Paul D. Brown,Edward G. Shaw,Jan C. Buckner +11 more
TL;DR: The results strongly suggest that a t(1;19)(q10;p10) mediates the combined 1p/19q deletion in human gliomas and the 1;19 translocation is associated with superior OS and progression-free survival in low-grade glioma patients.
Journal ArticleDOI
Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
Gregory Cairncross,B. Berkey,Edward G. Shaw,Robert B. Jenkins,B. W. Scheithauer,David Brachman,Jan C. Buckner,Karen Fink,Luis Souhami,Normand Laperierre,Minesh P. Mehta,W. Curran +11 more
TL;DR: For patients with AO and AOA, PCVplus RT does not prolong survival, and longer progression-free survival after PCV plus RT is associated with significant toxicity.